Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) Overview 9 Therapeutics Development 10 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Stage of Development 10 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Therapy Area 11 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Indication 12 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Companies 16 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Products under Development by Universities/Institutes 19 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Assessment 21 Assessment by Monotherapy/Combination Products 21 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Companies Involved in Therapeutics Development 28 Aileron Therapeutics, Inc. 28 CASI Pharmaceuticals Inc. 29 Cerulean Pharma, Inc. 30 Daiichi Sankyo Company, Limited 31 F. Hoffmann-La Roche Ltd. 32 InterMed Discovery GmbH 33 OncoImmune, Inc. 34 Peloton Therapeutics, Inc. 35 RXi Pharmaceuticals Corporation 36 Sorrento Therapeutics, Inc. 37 Transcriptogen Ltd 38 Vascular Biogenics Ltd. 39 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Drug Profiles 40 A-503451A - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Antisense RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Oncology - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Antisense RNAi Oligonucleotide to Inhibit SOX4 and HIF-1 Alpha for Metastatic Ovarian Cancer - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 ATSP-9172 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 BC-001 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 CASI-2ME2 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 CRLX-101 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Echinomycin - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 HS-1793 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 IMD-026259 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 KCN-1 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 MPT-0B098 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 RG-6061 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Small Molecule to Inhibit HIF-1 Alpha for Oncology - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 SR-16388 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 TR-764 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 TSG-1900 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 VB-411 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Dormant Projects 73 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Discontinued Products 77 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Featured News & Press Releases 78 Jul 19, 2016: Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer 78 Jun 22, 2016: Cerulean Announces Publication in Cancer Research 78 Jun 09, 2016: Cerulean Announces Manuscript Published in Annals of Oncology 79 May 19, 2016: Cerulean Announces Oral Presentation on Phase 1b results of CRLX101 at Gynecologic Oncology 2016 Conference 80 May 10, 2016: Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA 80 Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference 81 Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer 82 Mar 23, 2016: Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue 84 Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting 85 Nov 09, 2015: Cerulean Announces Data at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 87 Oct 27, 2015: Cerulean Announces Poster Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 88 Oct 19, 2015: Cerulean Announces First Patient Dosed in Clinical Trial to Evaluate Weekly Dosing Schedule with CRLX101 89 Oct 15, 2015: Cerulean Announces Completion of Enrollment of Randomized Phase 2 Trial of CRLX101 in Combination with Avastin in Relapsed Renal Cell Carcinoma 89 Sep 30, 2015: Cerulean Announces CRLX101 Advances to Second Stage of Phase 2 Clinical Trial of CRLX101 in Combination with Avastin in Relapsed Ovarian Cancer 90 Jul 21, 2015: Cerulean Announces First Patient Dosed in Phase 1b Trial of CRLX101 in Combination with Weekly Paclitaxel in Relapsed Ovarian Cancer 90 Appendix 92 Methodology 92 Coverage 92 Secondary Research 92 Primary Research 92 Expert Panel Validation 92 Contact Us 92 Disclaimer 93

List of Tables Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Early Stage Products, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Investigation by Universities/Institutes, H2 2016 19 Products under Investigation by Universities/Institutes, H2 2016 20 Assessment by Monotherapy/Combination Products, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Pipeline by Aileron Therapeutics, Inc., H2 2016 28 Pipeline by CASI Pharmaceuticals Inc., H2 2016 29 Pipeline by Cerulean Pharma, Inc., H2 2016 30 Pipeline by Daiichi Sankyo Company, Limited, H2 2016 31 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 32 Pipeline by InterMed Discovery GmbH, H2 2016 33 Pipeline by OncoImmune, Inc., H2 2016 34 Pipeline by Peloton Therapeutics, Inc., H2 2016 35 Pipeline by RXi Pharmaceuticals Corporation, H2 2016 36 Pipeline by Sorrento Therapeutics, Inc., H2 2016 37 Pipeline by Transcriptogen Ltd, H2 2016 38 Pipeline by Vascular Biogenics Ltd., H2 2016 39 Dormant Projects, H2 2016 73 Dormant Projects (Contd..1), H2 2016 74 Dormant Projects (Contd..2), H2 2016 75 Dormant Projects (Contd..3), H2 2016 76 Discontinued Products, H2 2016 77 List of Figures Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Top 10 Indication, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 21 Number of Products by Mechanism of Actions, H2 2016 22 Number of Products by Stage and Mechanism of Actions, H2 2016 22 Number of Products by Routes of Administration, H2 2016 24 Number of Products by Stage and Routes of Administration, H2 2016 24 Number of Products by Molecule Types, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 26

Aileron Therapeutics, Inc. CASI Pharmaceuticals Inc. Cerulean Pharma, Inc. Daiichi Sankyo Company, Limited F. Hoffmann-La Roche Ltd. InterMed Discovery GmbH OncoImmune, Inc. Peloton Therapeutics, Inc. RXi Pharmaceuticals Corporation Sorrento Therapeutics, Inc. Transcriptogen Ltd Vascular Biogenics Ltd.